<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02805374</url>
  </required_header>
  <id_info>
    <org_study_id>1517-CL-0202</org_study_id>
    <nct_id>NCT02805374</nct_id>
  </id_info>
  <brief_title>A Food Effect Study to Evaluate the Pharmacokinetics of ASP1517</brief_title>
  <official_title>ASP1517 Pharmacokinetic Study - Evaluation of Food Effect on the Pharmacokinetics of ASP1517</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>FibroGen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the effect of food on the pharmacokinetics of a&#xD;
      single oral dose of ASP1517 in non-elderly healthy adult male subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2016</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics (PK) parameter of ASP1517 in Plasma: AUCinf</measure>
    <time_frame>Up to Day 4 of each treatment period</time_frame>
    <description>AUCinf: Area under the concentration-time curve from the time of dosing extrapolated to time infinity</description>
  </primary_outcome>
  <primary_outcome>
    <measure>PK parameter of ASP1517 in Plasma: Cmax</measure>
    <time_frame>Up to Day 4 of each treatment period</time_frame>
    <description>Cmax: Maximum concentration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP1517 in Plasma: AUClast</measure>
    <time_frame>Up to Day 4 of each treatment period</time_frame>
    <description>AUClast: Area under the concentration-time curve from the time of dosing to the last measurable concentration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP1517 in Plasma: CL/F</measure>
    <time_frame>Up to Day 4 of each treatment period</time_frame>
    <description>CL/F: Apparent total systemic clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP1517 in Plasma: λz</measure>
    <time_frame>Up to Day 4 of each treatment period</time_frame>
    <description>λz: Terminal rate constant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP1517 in Plasma: MRTinf</measure>
    <time_frame>Up to Day 4 of each treatment period</time_frame>
    <description>MRTinf: Mean residence time extrapolated to infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP1517 in Plasma: t1/2</measure>
    <time_frame>Up to Day 4 of each treatment period</time_frame>
    <description>t1/2: Terminal elimination half-life</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP1517 in Plasma: tmax</measure>
    <time_frame>Up to Day 4 of each treatment period</time_frame>
    <description>tmax: Time of Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP1517 in Plasma: tlag</measure>
    <time_frame>Up to Day 4 of each treatment period</time_frame>
    <description>tlag: Lag time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP1517 in Plasma: Vz/F</measure>
    <time_frame>Up to Day 4 of each treatment period</time_frame>
    <description>Vz/F: Apparent volume of distribution during the terminal elimination phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP1517 in Urine: Ae</measure>
    <time_frame>Up to Day 4 of each treatment period</time_frame>
    <description>Ae: Cumulative amount of ASP1517 excreted into urine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK parameter of ASP1517 in Urine: CLR</measure>
    <time_frame>Up to Day 4 of each treatment period</time_frame>
    <description>CLR: Renal clearance</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety assessed by adverse events</measure>
    <time_frame>Up to Day 9 of Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal vital signs and/or adverse events during treatment period</measure>
    <time_frame>Up to Day 9 of Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal laboratory values and/or adverse events during treatment period</measure>
    <time_frame>Up to Day 9 of Period 2</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with abnormal standard 12-Lead ECG and/or adverse events during treatment period</measure>
    <time_frame>Up to Day 9 of Period 2</time_frame>
    <description>ECG: Electrocardiogram</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>ASP1517 fasting then fed</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single oral dose of ASP1517 under fasting conditions in period 1, then subjects will receive a single oral dose of ASP1517 under fed conditions in period 2.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP1517 fed then fasting</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will receive a single oral dose of ASP1517 under fed conditions in period 1, then subjects will receive a single oral dose of ASP1517 under fasting conditions in period 2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP1517</intervention_name>
    <description>Oral</description>
    <arm_group_label>ASP1517 fasting then fed</arm_group_label>
    <arm_group_label>ASP1517 fed then fasting</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Body weight: ≥50.0 kg and &lt;80.0 kg&#xD;
&#xD;
          -  Body-mass index : ≥17.6 and &lt;26.4 kg/m2&#xD;
&#xD;
          -  Subject must agree to use two of the established contraceptive methods after informed&#xD;
             consent acquisition through 84 days after the last administration of the study drug.&#xD;
&#xD;
          -  Subject must agree not to donate sperm after informed consent acquisition through 84&#xD;
             days after the last administration of the study drug.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Received or is scheduled to receive any investigational drugs in other clinical trials&#xD;
             or post-marketing studies within 120 days before screening or during the period from&#xD;
             screening to the hospital admission day of Period 1&#xD;
&#xD;
          -  Received or is scheduled to receive medications (including over-the-counter [OTC]&#xD;
             drugs) within 7 days before the hospital admission day of Period 1&#xD;
&#xD;
          -  Received or is scheduled to receive supplements within 7 days before the hospital&#xD;
             admission day of the Period 1&#xD;
&#xD;
          -  Deviates from any of the normal range of blood pressure, pulse rate, body temperature&#xD;
             and standard 12-lead electrocardiogram (ECG) at screening or the hospital admission&#xD;
             day of Period 1&#xD;
&#xD;
          -  Meets any of the criteria for laboratory tests at screening or the hospital admission&#xD;
             day of Period 1. Normal ranges of each test specified at the test/assay organization&#xD;
             will be used as the normal ranges in this study.&#xD;
&#xD;
          -  Concurrent or previous drug allergies.&#xD;
&#xD;
          -  Development of (an) upper gastrointestinal symptom(s) within seven days before the&#xD;
             hospital admission day of Period 1.&#xD;
&#xD;
          -  Concurrent or previous hepatic disease, heart disease, respiratory disease,&#xD;
             gastrointestinal disease, renal disease, endocrine disease, cerebrovascular disorder,&#xD;
             malignant tumor, retinal neovascular lesions and macular edema.&#xD;
&#xD;
          -  A history of digestive tract excision.&#xD;
&#xD;
          -  Previous use of hypoxia inducible factor-prolyl hydroxylase inhibitors (HIF-PHI) such&#xD;
             as ASP1517 (FG-4592), YM311(FG-2216) or erythropoietin products.&#xD;
&#xD;
          -  Excessive alcohol or smoking habit.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>44 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site JP00001</name>
      <address>
        <city>Tokyo</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>August 2016</verification_date>
  <study_first_submitted>June 16, 2016</study_first_submitted>
  <study_first_submitted_qc>June 16, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 20, 2016</study_first_posted>
  <last_update_submitted>August 22, 2016</last_update_submitted>
  <last_update_submitted_qc>August 22, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 24, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pharmacokinetics</keyword>
  <keyword>ASP1517</keyword>
  <keyword>Food effect</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

